Olaratumab + Doxorubicin for Metastatic Soft-Tissue Sarcoma
1 Görünümler
• 07/18/23
0
0
gömmek
administrator
Aboneler
William D. Tap, MD; Richard F. Riedel, MD; Victor M. Villalobos, MD, PhD; and Kristen N. Ganjoo, MD, comment on the overall survival benefit seen in the phase II study of doxorubicin and olaratumab, the phase III ANNOUNCE trial, and patient selection for this regimen and data for other regimens.
Daha fazla göster
Facebook Yorumları
SORT BY-
En Çok Yorumlananlar
-
Son Yorumlar